PhaseBio Pharmaceuticals, Inc. Gains 32.22%
PhaseBio Pharmaceuticals, Inc. (PHAS:NASDAQ) shot up at $1.19, representing a gain of 32.2%. On Fri, Jul 08, 2022, PHAS:NASDAQ touched a New 2-Week High of $1.19. From Fri, Jun 24, 2022, the stock recorded 77.78% Up Days and 80.00% Green Days
About PhaseBio Pharmaceuticals, Inc. (PHAS:NASDAQ)
PhaseBio Pharmaceuticals Inc is a clinical-stage bio-pharmaceutical company. It is focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. The lead product candidate of the company is PB2452, which is a novel reversal agent for the antiplatelet drug ticagrelor, used for the treatment of patients experiencing major bleeding or those who require urgent surgery. It is also developing PB1046, a fusion protein currently in a Phase 2b clinical trial for the treatment of pulmonary arterial hypertension.
Top 10 Gainers:
- Seritage Growth Properties (SRG:NYSE), 80.26%
- Aditxt Inc. (ADTX:NASDAQ), 50%
- Waitr Holdings Inc. (WTRH:NASDAQ), 48.49%
- Oramed Pharmaceuticals Inc. (ORMP:NASDAQ), 44.37%
- Agrico Acquisition Corp. (RICO:NASDAQ), 43.66%
- MyMD Pharmaceuticals Inc. (MYMD:NASDAQ), 42.14%
- Kura Sushi USA, Inc. (KRUS:NASDAQ), 33.62%
- PhaseBio Pharmaceuticals, Inc. (PHAS:NASDAQ), 32.22%
- Organovo Holdings, Inc. (ONVO:NASDAQ), 29.17%
- Immuneering Corporation (IMRX:NASDAQ), 28.85%